A Retrospective Single-Center Study on Postoperative Radiotherapy Without Internal Mammary Node Irradiation in pT1–2N1M0 Breast Cancer

Background Whether internal mammary node irradiation (IMNI) should be routinely included in postoperative radiotherapy for pT1–2N1M0 breast cancer remains controversial. Randomized evidence is inconsistent, while observational data suggest that benefit may be restricted to specific subgroups. Methods We conducted a retrospective cohort study of 648 patients treated between January 2010 and December 2015 at a single center. All patients underwent curative surgery (mastectomy or breast-conserving surgery) and received postoperative 3-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiotherapy (IMRT), but without IMNI. The primary endpoint was disease-free survival (DFS); secondary endpoints included overall survival (OS), distant disease-free survival (DDFS), and breast cancer–specific survival (BCSS). Survival was estimated using Kaplan–Meier methods, and prognostic factors were assessed with univariate and multivariable Cox proportional hazards models. Results At 10 years, DFS, OS, DDFS, and BCSS were 83.7%, 90.0%, 84.8%, and 93.1%, respectively. In multivariable analyses, triple-negative molecular subtype was the strongest independent adverse factor across endpoints (OS HR = 3.750, P < 0.001; BCSS HR = 3.971, P < 0.001). Age ≤ 40 years (BCSS HR = 0.461, P = 0.027) and lymphovascular invasion positivity (BCSS HR = 2.325, P = 0.010) were independently associated with poorer outcomes. Anthracycline plus taxane–based chemotherapy independently improved OS/DFS/DDFS. Conclusion In patients with pT1–2N1M0 breast cancer who did not receive IMNI, triple-negative subtype, age ≤ 40 years, and LVI positivity identify individuals with significantly worse prognosis, supporting individualized IMN decision-making.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-18
DOI
https://doi.org/10.21203/rs.3.rs-11273988/v1
Primary Topic
Breast Cancer Treatment Studies
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

A Retrospective Single-Center Study on Postoperative Radiotherapy Without Internal Mammary Node Irradiation in pT1–2N1M0 Breast Cancer

Xianglu Zhu, Youxi Han, Junxiao Chen, 王义海 et al.
3 links
Research Square
Breast Cancer Treatment Studies
preprint

A Retrospective Single-Center Study on Postoperative Radiotherapy Without Internal Mammary Node Irradiation in pT1–2N1M0 Breast Cancer

Xianglu Zhu, Youxi Han, Junxiao Chen, 王义海, Shaya Nazihan
preprint en

Abstract

Background Whether internal mammary node irradiation (IMNI) should be routinely included in postoperative radiotherapy for pT1–2N1M0 breast cancer remains controversial. Randomized evidence is inconsistent, while observational data suggest that benefit may be restricted to specific subgroups. Methods We conducted a retrospective cohort study of 648 patients treated between January 2010 and December 2015 at a single center. All patients underwent curative surgery (mastectomy or breast-conserving surgery) and received postoperative 3-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiotherapy (IMRT), but without IMNI. The primary endpoint was disease-free survival (DFS); secondary endpoints included overall survival (OS), distant disease-free survival (DDFS), and breast cancer–specific survival (BCSS). Survival was estimated using Kaplan–Meier methods, and prognostic factors were assessed with univariate and multivariable Cox proportional hazards models. Results At 10 years, DFS, OS, DDFS, and BCSS were 83.7%, 90.0%, 84.8%, and 93.1%, respectively. In multivariable analyses, triple-negative molecular subtype was the strongest independent adverse factor across endpoints (OS HR = 3.750, P < 0.001; BCSS HR = 3.971, P < 0.001). Age ≤ 40 years (BCSS HR = 0.461, P = 0.027) and lymphovascular invasion positivity (BCSS HR = 2.325, P = 0.010) were independently associated with poorer outcomes. Anthracycline plus taxane–based chemotherapy independently improved OS/DFS/DDFS. Conclusion In patients with pT1–2N1M0 breast cancer who did not receive IMNI, triple-negative subtype, age ≤ 40 years, and LVI positivity identify individuals with significantly worse prognosis, supporting individualized IMN decision-making.

Research Square
Tumor Hospital of Xinjiang Medical University (CN)
Xinjiang Medical University
Good health and well-being
Breast Cancer Treatment Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon